Page 1,435«..1020..1,4341,4351,4361,437..1,4401,450..»

Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated – Yahoo Finance

Posted: Published on September 18th, 2019

Dublin, Sept. 16, 2019 (GLOBE NEWSWIRE) -- The "Nitric Oxide - Therapeutics, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report contains information on the following: NO Pathways Role of NO in Physiology Role of NO in Disease Pharmacology Therapeutic Applications Evaluation of NO-based drugs Markets for NO-based Therapies Companies involved in NO therapeutics The report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated – Yahoo Finance

Cardiac fibrosis study identifies key proteins that translate into heart disease – BSA bureau

Posted: Published on September 18th, 2019

The formation of excess fibrous tissue in the heart, which underlies several heart diseases, could be prevented by inhibiting specific proteins that bind to RNA while its code is being translated Using cutting-edge technologies, researchers at Duke-NUS Medical School, Singapore, have developed the first genome-wide dataset on protein translation during fibroblast activation, revealing a network of RNA-binding proteins (RBPs) that play a key role in the formation of disease-causing fibrous tissue in the heart. Their findings, published in the journal Circulation, could help in the search for treatments for this condition. Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Cardiac fibrosis study identifies key proteins that translate into heart disease – BSA bureau

Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 – Yahoo Finance

Posted: Published on September 18th, 2019

-Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide) -Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA in patients with metastatic castration-sensitive prostate cancer -Interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer and biallelic DNA-repair gene defects, featured as late-breaking abstract RARITAN, N.J., Sept. 17, 2019 /PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen's 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 – Yahoo Finance

Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) – BioSpace

Posted: Published on September 18th, 2019

Sept. 12, 2019 10:31 UTC CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. mRNA-1944 encodes for an antibody (CHKV-24) with activity against chikungunya virus Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) – BioSpace

Pharmacokinetics Market To Increase at Steady Growth Rate – Commerce Gazette

Posted: Published on September 18th, 2019

Pharmacokinetics is currently defined as the branch of pharmacology concerned with the study of the time course of drug distribution, absorption, metabolism and excretion. Pharmacokinetics is derived from the Greek word pharmacon (drug) and kineticos (motion) Drugs aims to prevent, cure or control various diseases states. To achieve this goal suitable concentration of medicine must be delivered to the target tissues so that will be beneficial, yet nontoxic levels are obtained Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Pharmacokinetics Market To Increase at Steady Growth Rate – Commerce Gazette

Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 – Market Report Gazette

Posted: Published on September 18th, 2019

Microbiomes are used for metabolism and immunity. In the human body, microbes are used as a factory to produce drugs, a machine for perforated action, a vehicle for drug delivery and are sometimes considered drugs. Microbiomes are used to treat various diseases, such as autoimmune diseases and gastrointestinal diseases Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 – Market Report Gazette

Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of…

Posted: Published on September 18th, 2019

Pharmacogenomics (PGx) Market Report has newly added to its massive repository. Different industry-specific methods have been used for analyzing the market carefully Continue reading

Posted in Cardiovascular Pharmacology | Comments Off on Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of…

Bryon Riesch Paralysis Foundation gives $1.25 million to Medical College of Wisconsin – BizTimes – Milwaukee Business News

Posted: Published on September 18th, 2019

The Waukesha-based Bryon Riesch Paralysis Foundation is giving $1.25 million for neuroscience research at the Medical College of Wisconsin. Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Bryon Riesch Paralysis Foundation gives $1.25 million to Medical College of Wisconsin – BizTimes – Milwaukee Business News

Fundraiser aims to help people walk again – santaynezvalleystar.com

Posted: Published on September 18th, 2019

Will Ambler and SCI Research Advancement have launched a GoFundMe campaign. By Pamela Dozois Contributing Writer A small group of dedicated people have started a GoFundMe Campaign to raise $125,000 for creating a therapy that could help people with spinal cord injuries regain the ability to stand and walk Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Fundraiser aims to help people walk again – santaynezvalleystar.com

First Digital Therapeutics Solution for Orthopedics Recovery to be presented at Clinical Orthopedics Society (COS) 2019 Annual Meeting – P&T Community

Posted: Published on September 18th, 2019

BRIDGEWATER, N.J., Sept. 17, 2019 /PRNewswire/ -- JOGO Health Inc., a privately held digital therapeutics company focused on the development and commercialization oftreatments for neuromuscular (NM), incontinence and orthopedics conditions today announced that it will present evidence and performance of its lead investigational product JOGO, at the 2019 Clinical Orthopedics Society's (COS) 107th Annual Scientific Meeting held at Omni at The Battery, Atlanta, GAfrom 18 -21 September 2019. The oral presentation titled "Digital Therapeutics (DTx) EMG Biofeedback Solution for Post-Scapular Fracture" will be presented during the Rapid Fire Sessions 3A under Shoulder & Elbow in the Mathews Room, moderated by Champ L. Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on First Digital Therapeutics Solution for Orthopedics Recovery to be presented at Clinical Orthopedics Society (COS) 2019 Annual Meeting – P&T Community

Page 1,435«..1020..1,4341,4351,4361,437..1,4401,450..»